

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-81. (canceled)

82. (previously presented) A method of treating a subject having an angiogenesis-dependent tumor, the method comprising:
identifying a subject having an angiogenesis-dependent tumor; and
administering to the subject a cell genetically engineered to express TSP-2 (SEQ ID NO:2) or a fragment thereof, capable of inhibiting endothelial cell migration, wherein the fragment comprises at least 10 contiguous amino acids of either a procollagen domain of TSP-2 or a type I repeat of TSP-2.

83-86. (canceled)

87. (currently amended) The method of claim ~~86~~ 82, wherein the cell is autologous.

88. (currently amended) The method of claim ~~86~~ 82, wherein the cell is allogeneic.

89. (currently amended) The method of claim ~~86~~ 82, wherein the cell is xenogeneic.

90. (currently amended) The method of claim 82 ~~or 86~~, wherein the cell is an epithelial cell.

91. (currently amended) The method of claim 82 ~~or 86~~, wherein the cell is selected from the group consisting of: a fibroblast, a keratinocyte, an endothelial cell, a glial cell, a neural cell, a lymphocyte, a bone marrow cell, and a muscle cell.

92. (currently amended) The method of claim ~~86~~ 82, wherein the level of TSP-2 or fragment thereof in the subject after administration is increased for at least 2 days.

93. (currently amended) The method of claim ~~86~~ 82, wherein the level of TSP-2 in the subject after administration is increased for at least 10 days.

94. (currently amended) The method of claim ~~86~~ 82, wherein the level of TSP-2 in the subject after administration is increased for at least 14 days.

95. (currently amended) The method of claim ~~86~~ 82, wherein the level of TSP-2 in the subject after administration is increased for at least 30 days.

96. (currently amended) The method of claim ~~86~~ 82, wherein the tumor is selected from the group consisting of: melanoma, a prostate tumor, a breast tumor, a colon tumor, and a lung tumor.

97. (previously presented) The method of claim 82, wherein the subject is a human.

98. (canceled)

99. (previously presented) A method of treating a subject having an angiogenesis-dependent tumor, the method comprising:

administering to the subject a cell genetically modified to express TSP-2 (SEQ ID NO:2).

100. (new) The method of claim 82, wherein the cell is genetically engineered to express a fragment of TSP-2 capable of inhibiting endothelial cell migration, wherein the fragment comprises at least 10 contiguous amino acids of a procollagen domain.

101. (new) The method of claim 82, wherein the cell is genetically engineered to express a fragment of TSP-2 capable of inhibiting endothelial cell migration, wherein the fragment comprises at least 10 contiguous amino acids of a type I repeat of TSP-2.